Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.

Abstract excerpt

BACKGROUND AND AIM: To evaluate the optimal dosage of rabeprazole for proton-pump inhibitor (PPI) testing of gastroesophageal reflux disease (GERD) and to test the influence of cytochrome P450 (CYP) 2C19 polymorphism in a population with a high prevalence of people who metabolize PPI poorly. METHODS: In this randomized, open-label trial, patients with symptoms suggestive of GERD were randomized to receive a...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to 2-Pyridinylmethylsulfinylbenzimidazoles
• Share to Anti-Ulcer Agents